Vaxart (NASDAQ: VXRT) has been involved in the coronavirus vaccine race since the beginning. It's developing what could be a game-changing option: a vaccine in pill form. That's why this biotech player has been one to watch.
That potential product is now involved in phase 2 studies. That's as rivals Pfizer and Moderna have gained dominance in the market worldwide. And latecomer Novavax even reported its first quarterly profit recently -- after just one quarter of selling its vaccine.
All of this means there is one big problem for Vaxart right now. The question is: Could it hurt the company's prospects over the long term? Let's find out.
Source Fool.com